# 20/20 BIOLABS, INC. (AIDX) · Edgar & Edgarette company card

> 20/20 Biolabs (AIDX) grew revenue 16.7% in FY2025 to $2 million, operating margin -163% against a 14.9% median for testing laboratories, equity -0.5% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1139685 · fiscal year ended 2025-12-31 · 2 audited years read · [page](https://www.pops4.com/boards/company/AIDX) · [JSON](https://www.pops4.com/boards/company/AIDX.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $2M |
| Revenue growth, 1 year | 16.7% |
| Revenue growth per year | — |
| Operating margin | -162.9% (prior year -324.0%) |
| Net margin | -182.8% |
| Operating cash flow | −$2M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $1M |
| Long-term debt | — |
| Total assets | $4M |
| Total equity | −$19,225 |
| Equity ÷ assets | -0.5% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -33.18 (distress zone)
- Piotroski F: 5 of 9 (middling)
- Beneish M: -4.2 (below the −1.78 line)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed late quarterly report notice in the last 12 months; liabilities exceed assets (often from years of share buybacks, not always distress); operating cash flow was negative; operating loss: a margin of -162.9% in FY2025; revenue is hard to predict: its 80% range is ±28%

## Edgarette's reading

Exposure: revenue $2.0M (FY2025). Experience: revenue up 16.7% on the year; operating margin -162.9%, up from -324.0%. Soundness: equity -0.5% of assets (liabilities exceed assets). Credibility: 2 audited years, moderate weight. Range: 80% of past cases like this landed between $1.8M and $3.1M next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (8 filers, $50M+ revenue, its industry group): operating margin -162.9% against a 14.9% median; growth 16.7% against 5.2%.

Range logged 2026-09-20, receipt ce5bb3875232b3a9, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 2, latest 2026-09-10 ([filing](https://www.sec.gov/Archives/edgar/data/1139685/000121390026098792/0001213900-26-098792-index.htm))
- Item NT 10-Q Late quarterly report notice: 1, latest 2026-05-15 ([filing](https://www.sec.gov/Archives/edgar/data/1139685/000121390026057812/0001213900-26-057812-index.htm))

## Recent filings

- DEF 14A · filed 2026-10-21 · [filing](https://www.sec.gov/Archives/edgar/data/1139685/000121390026111346/0001213900-26-111346-index.htm)
- 8-K · filed 2026-09-18 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/1139685/000121390026101405/0001213900-26-101405-index.htm)
- 8-K · filed 2026-09-10 · 3.01 Notice of Delisting or Failure to Satisfy a Listing Rule · [filing](https://www.sec.gov/Archives/edgar/data/1139685/000121390026098792/0001213900-26-098792-index.htm)
- 8-K · filed 2026-09-02 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1139685/000121390026096743/0001213900-26-096743-index.htm)
- 8-K · filed 2026-08-19 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/1139685/000121390026091438/0001213900-26-091438-index.htm)
- 8-K · filed 2026-08-17 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1139685/000121390026090746/0001213900-26-090746-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001139685.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1139685

## Cite

POPS4, Edgar & Edgarette: 20/20 BIOLABS, INC. (AIDX) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/AIDX. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.